Patients with severe anemia secondary to CKD < Hb 9.0 gm/dl and those with advanced CKD, for example those on regular HD, need prolonged periods of ESA therapy to improve their QoL, to prevent anemia-related symptoms, and to minimize the need for blood transfusion [8]. The gene discussed is GSTM1; the disease is chronic kidney disease.